Search in:

Advanced search

Cancer Biology & Therapy Volume 17, 2016 - Issue 6

Submit an article Journal homepage

Free access

1,126

Views

CrossRef citations to date

Altmetric

Research Paper

Remarkable response in 2 cases of Advanced Poorly Differentiated Thyroid Carcinoma with liposomal doxorubicin plus cisplatin

Haiyan YangChemotherapy Center, Zhejiang Province Cancer Hospital, Hangzhou, PRChina

Zhongjian ChenLaboratory of Clinical Pharmacy, Zhejiang Province Cancer Hospital, Hangzhou, PRChina

Meijuan WuDepartment of Pathology, Zhejiang Province Cancer Hospital, Hangzhou, PRChina

Tao LeiChemotherapy Center, Zhejiang Province Cancer Hospital, Hangzhou, PRChina

Haifeng YuChemotherapy Center, Zhejiang Province Cancer Hospital, Hangzhou, PRChina

Minghua GeDepartment of Head and Neck Surgery, Zhejiang Province Cancer Hospital, Hangzhou, PRChinaCorrespondence[email protected]

Pages 693-697 | Received 19 Jan 2016, Accepted 13 Mar 2016, Published online: 14 Jun 2016

Cite this article
https://doi.org/10.1080/15384047.2016.1167295
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions
View PDF PDF

Reference

Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 1983; 52:1849-55; PMID:6313176; http://dx.doi.org/10.1002/1097-0142(19831115)52:10<1849::AID-CNCR2820521015>3.0.CO;2-X
PubMed Web of Science ®Google Scholar
Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007; 31:1256-64; PMID:17667551; http://dx.doi.org/10.1097/PAS.0b013e3180309e6a
PubMed Web of Science ®Google Scholar
Hannallah J, Rose J, Guerrero MA. Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma. Int J Endocrinol 2013; 2013:317487; PMID:23476646; http://dx.doi.org/10.1155/2013/317487
PubMedGoogle Scholar
Fat I, Kulaga M, Dodis R, Carling T, Theoharis C, Rennert NJ. Insular variant of poorly differentiated thyroid carcinoma. Endocr Pract 2011; 17:115-21; PMID:20634178; http://dx.doi.org/10.4158/EP09368.RA
PubMed Web of Science ®Google Scholar
Soares P, Lima J, Preto A, Castro P, Vinagre J, Celestino R, Couto JP, Prazeres H, Eloy C, Máximo V, et al. Genetic alterations in poorly differentiated and undifferentiated thyroid carcinomas. Curr Genomics 2011; 12:609-17; PMID:22654560; http://dx.doi.org/10.2174/138920211798120853
PubMed Web of Science ®Google Scholar
Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26:4714-9; PMID:18541894; http://dx.doi.org/10.1200/JCO.2008.16.3279
PubMed Web of Science ®Google Scholar
Carr LL, Mankoff DA, Goulart BH, Eaton K D, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010; 16:5260-8; PMID:20847059; http://dx.doi.org/10.1158/1078-0432.CCR-10-0994
PubMed Web of Science ®Google Scholar
Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56:2155-60; PMID:3902203; http://dx.doi.org/10.1002/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E
PubMed Web of Science ®Google Scholar
Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986; 70:405-7; PMID:3955552
PubMedGoogle Scholar
Spano JP, Vano Y, Vignot S, De La Motte Rouge T, Hassani L, Mouawad R, Menegaux F, Khayat D, Leenhardt L. GEMOX regimen in the treatment of metastatic differentiated refractory thyroid carcinoma. Med Oncol 2012; 29:1421-8; PMID:21947747; http://dx.doi.org/10.1007/s12032-011-0070-2
PubMed Web of Science ®Google Scholar
Markman M. Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother 2006; 7:1469-74; PMID:16859430; http://dx.doi.org/10.1517/14656566.7.11.1469
PubMed Web of Science ®Google Scholar
Moscetti L, Padalino D, Capomolla E, Nelli F, Pollera CF. A partial response in anaplastic carcinoma of the thyroid with liposomal doxorubicin. J Exp Clin Cancer Res 2005; 24:151-4; PMID:15943045
PubMed Web of Science ®Google Scholar
Gottlieb JA, Hill CS, Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 1974; 290:193-7; PMID:4808917; http://dx.doi.org/10.1056/NEJM197401242900404
PubMed Web of Science ®Google Scholar
Robbins J, Merino MJ, Boice JD, Jr, Ron E, Ain KB, Alexander HR, Norton JA, Reynolds J. Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 1991; 115:133-47; PMID:2058861; http://dx.doi.org/10.7326/0003-4819-115-2-133
PubMed Web of Science ®Google Scholar
Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008; 34:592-602; PMID:18538481; http://dx.doi.org/10.1016/j.ctrv.2008.04.003
PubMed Web of Science ®Google Scholar
Kopecka J, Salzano G, Campia I, Lusa S, Ghigo D, De Rosa G, Riganti C. Insights in the chemical components of liposomes responsible for P-glycoprotein inhibition. Nanomedicine 2014; 10:77-87; PMID:23850894; http://dx.doi.org/10.1016/j.nano.2013.06.013
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Remarkable response in 2 cases of Advanced Poorly Differentiated Thyroid Carcinoma with liposomal doxorubicin plus cisplatin

Reference

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Remarkable response in 2 cases of Advanced Poorly Differentiated Thyroid Carcinoma with liposomal doxorubicin plus cisplatin

Reference

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date